Gilead clos­es $247M HIV drug set­tle­ment deal

A Cal­i­for­nia fed­er­al judge on Fri­day ap­proved a near­ly $247 mil­lion plan to set­tle claims that Gilead wrong­ful­ly kept gener­ic HIV com­peti­tors from the mar­ket.

Gilead will pay the amount to a set­tle­ment fund, which rep­re­sents about 11.9% of the dam­ages plain­tiffs were seek­ing at tri­al. Pur­chasers of Gilead’s HIV treat­ments filed suit in 2019 al­leg­ing the com­pa­ny had a “stran­gle­hold” on the com­bi­na­tion an­ti­retro­vi­ral ther­a­py mar­ket, caus­ing con­sumers to pay in­flat­ed prices and sti­fling in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER